Treatment of refractory polymyositis and dermatomyositis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases that primarily target muscle. Although similar, PM and DM have different pathophysiologic mechanisms. Current therapy for PM and DM does not take into account these pathophysiologic differences. Recent work has started to define outcome measures to apply to future therapeutic trials, which will allow better comparison of treatment outcomes. For patients who are unresponsive to standard therapy with high dose prednisone supplemented by methotrexate and/or azathioprine it is not clear what represents the next best choice for therapy. Although there are few controlled studies in the area, there is reason to be optimistic for use of intravenous methylprednisolone pulses, intravenous gammaglobulin, cyclosporine A, tacrolimus, mycophenolate mofetil, and rituximab for nonresponding patients. Better understanding of the underlying pathophysiology of PM and DM, as well as carefully performed multicenter clinical trials is going to be necessary to make better recommendations in the future.

Original languageEnglish (US)
Pages (from-to)167-173
Number of pages7
JournalCurrent Rheumatology Reports
Volume8
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Dermatomyositis
Mycophenolic Acid
Methylprednisolone
Azathioprine
Tacrolimus
Therapeutics
Prednisone
Methotrexate
Cyclosporine
Autoimmune Diseases
Multicenter Studies
Outcome Assessment (Health Care)
Clinical Trials
Muscles

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment of refractory polymyositis and dermatomyositis. / Ytterberg, Steven R.

In: Current Rheumatology Reports, Vol. 8, No. 3, 06.2006, p. 167-173.

Research output: Contribution to journalArticle

@article{0095967db84f442797709e9851f7ffde,
title = "Treatment of refractory polymyositis and dermatomyositis",
abstract = "Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases that primarily target muscle. Although similar, PM and DM have different pathophysiologic mechanisms. Current therapy for PM and DM does not take into account these pathophysiologic differences. Recent work has started to define outcome measures to apply to future therapeutic trials, which will allow better comparison of treatment outcomes. For patients who are unresponsive to standard therapy with high dose prednisone supplemented by methotrexate and/or azathioprine it is not clear what represents the next best choice for therapy. Although there are few controlled studies in the area, there is reason to be optimistic for use of intravenous methylprednisolone pulses, intravenous gammaglobulin, cyclosporine A, tacrolimus, mycophenolate mofetil, and rituximab for nonresponding patients. Better understanding of the underlying pathophysiology of PM and DM, as well as carefully performed multicenter clinical trials is going to be necessary to make better recommendations in the future.",
author = "Ytterberg, {Steven R}",
year = "2006",
month = "6",
doi = "10.1007/s11926-996-0021-7",
language = "English (US)",
volume = "8",
pages = "167--173",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment of refractory polymyositis and dermatomyositis

AU - Ytterberg, Steven R

PY - 2006/6

Y1 - 2006/6

N2 - Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases that primarily target muscle. Although similar, PM and DM have different pathophysiologic mechanisms. Current therapy for PM and DM does not take into account these pathophysiologic differences. Recent work has started to define outcome measures to apply to future therapeutic trials, which will allow better comparison of treatment outcomes. For patients who are unresponsive to standard therapy with high dose prednisone supplemented by methotrexate and/or azathioprine it is not clear what represents the next best choice for therapy. Although there are few controlled studies in the area, there is reason to be optimistic for use of intravenous methylprednisolone pulses, intravenous gammaglobulin, cyclosporine A, tacrolimus, mycophenolate mofetil, and rituximab for nonresponding patients. Better understanding of the underlying pathophysiology of PM and DM, as well as carefully performed multicenter clinical trials is going to be necessary to make better recommendations in the future.

AB - Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases that primarily target muscle. Although similar, PM and DM have different pathophysiologic mechanisms. Current therapy for PM and DM does not take into account these pathophysiologic differences. Recent work has started to define outcome measures to apply to future therapeutic trials, which will allow better comparison of treatment outcomes. For patients who are unresponsive to standard therapy with high dose prednisone supplemented by methotrexate and/or azathioprine it is not clear what represents the next best choice for therapy. Although there are few controlled studies in the area, there is reason to be optimistic for use of intravenous methylprednisolone pulses, intravenous gammaglobulin, cyclosporine A, tacrolimus, mycophenolate mofetil, and rituximab for nonresponding patients. Better understanding of the underlying pathophysiology of PM and DM, as well as carefully performed multicenter clinical trials is going to be necessary to make better recommendations in the future.

UR - http://www.scopus.com/inward/record.url?scp=33747585796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747585796&partnerID=8YFLogxK

U2 - 10.1007/s11926-996-0021-7

DO - 10.1007/s11926-996-0021-7

M3 - Article

C2 - 16901073

AN - SCOPUS:33747585796

VL - 8

SP - 167

EP - 173

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 3

ER -